Drug Profile
Icodextrin - Innovata/Takeda
Alternative Names: Adept®; Extraneal; Icodextrin solution; Icodial®Latest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Innovata
- Developer Baxter Healthcare Corporation; Takeda
- Class Glucans; Hexoses
- Mechanism of Action Triglyceride modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Kidney disorders
- No development reported Heart failure; Hypertriglyceridaemia
Most Recent Events
- 14 Apr 2021 No development reported - Phase-II for Hypertriglyceridaemia (In the elderly, In adults) in South Korea (Intraperitoneal)
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 11 Oct 2018 Clinical development is ongoing in Hypertriglyceridaemia (In adults, In the elderly) in South Korea (Intraperitoneal) (NCT02166359)